Class I Phosphatidylinositol 3-Kinases
-
Subject Areas on Research
- AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
- Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.
- Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.
- Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
- Comprehensive molecular portraits of human breast tumours.
- Genetic heterogeneity of diffuse large B-cell lymphoma.
- High frequency of mutations of the PIK3CA gene in human cancers.
- ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
- Leukaemia hijacks a neural mechanism to invade the central nervous system.
- Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
- Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
- Novel mutations target distinct subgroups of medulloblastoma.
- Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
- PIK3CA mutation in a mixed dysembryoplastic neuroepithelial tumor and rosette forming glioneuronal tumor, a case report and literature review.
- PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
- PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
- Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
- Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex.
- Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
- The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.